Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beximco PharmaceuticalsBXMPY 94 Return-on-Tangible-Asset is 12.07% as of Mar. 2026, which is 63% above its 10-year median of 7.41. GuruFocus rates BXMPY with a GF Score™ of 94/100. The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 84.21% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Beximco Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was $72.02 Mil. Beximco Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was $596.46 Mil. Therefore, Beximco Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 12.07%.
The historical rank and industry rank for Beximco Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
BXMPY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.72 Med: 7.41 Max: 10.53
Current: 12.12
During the past 13 years, Beximco Pharmaceuticals's highest Return-on-Tangible-Asset was 10.53%. The lowest was 6.72%. And the median was 7.41%.
BXMPY's Return-on-Tangible-Asset is ranked better than 84.21% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs BXMPY: 12.12
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Beximco Pharmaceuticals Return-on-Tangible-Asset Related Terms
Beximco Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Beximco Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BXMPY vs ZTS, UTHR: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.07% mean?
Beximco Pharmaceuticals (BXMPY) has a Return-on-Tangible-Asset of 12.07% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Beximco Pharmaceuticals and its competitors. This is 63% above median its historical median of 7.41. Over the past decade, Beximco Pharmaceuticals' Return-on-Tangible-Asset has ranged from 6.72 to 10.53. According to the industry distribution chart, Beximco Pharmaceuticals ranks #159 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 15.8%.
Is Beximco Pharmaceuticals' Return-on-Tangible-Asset too high?
Beximco Pharmaceuticals' current Return-on-Tangible-Asset of 12.07% is 63% above median its 10-year median of 7.41. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 10.53. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Beximco Pharmaceuticals' value of 12.07% is 282% above this industry median. Based on the distribution chart, Beximco Pharmaceuticals ranks #159 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #159 out of 1007 companies for Return-on-Tangible-Asset. This places Beximco Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. Beximco Pharmaceuticals' value of 12.07% is 282% above this benchmark. Historically, Beximco Pharmaceuticals' own Return-on-Tangible-Asset has ranged from 6.72 to 10.53 over the past decade. While the company's 10-year median is 7.41 vs. the industry median of 3.16, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current Return-on-Tangible-Asset of 12.07% is 282% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Return-on-Tangible-Asset is 12.07%, which is 63% above median its own 10-year median of 7.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Return-on-Tangible-Asset of 12.07%. The current Return-on-Tangible-Asset is 12.07%, which is 63% above median its 10-year median of 7.41 and 282% above the Drug Manufacturers industry median of 3.16. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Return-on-Tangible-Asset is 12.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 
